Font Size




Menu Style

AVG Home


AVG Webinar Series

AVG Webinar series

You can listen to the recordings from the AVG webinars which have taken place to date via the links below:

25 October 2022: Treatments/Antiviral Therapeutics - link to the recording

24 January 2023: Antiviral Resistance - link to the recording

20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording

30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording

2024 ISIRV Webinars

24 Jan

If you missed the webinar on 24 Jan on 'RSV Vaccination in the Elderly Population' you can register and watch the recording via this link 

20 March

If you missed this webinar on 'Emerging Influenza and the Human-Animal Interface' you can register and watch the recording via this link 

29 May

Webinar on ‘Recent antiviral developments for respiratory viral infections’

We’re delighted to announce that we’ll have 3 speakers on this webinar.

Professor Bin Cao, China-Japan Friendship Hospital, Beijing, China will give an overview talk on ‘Recent Antiviral Developments for Respiratory Viral Infections in China'.

Dr Tom Fletcher, Liverpool School of Tropical Medicine, Liverpool, UK who will speak on ‘IV favipirivir’

Dr Don Ganem, Via Nova Therapeutics, Oakland, CA, USA who will speak on 'VNT-101: A Novel, Orally Bioavailable Inhibitor of Influenza A Virus Targeting the Viral Nucleoprotein, NP'

You can register now via this link 


7th AVG Conference (in-person)

We’ve had some great feedback…. adobe pdf icon2

SARS-CoV-2 / COVID-19   
Antiviral News

AVG Overview

The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More


   isirv Antiviral Group (isirv-AVG) 10th Anniversary

The isirv Antiviral Group was established in 2011 following the merger of the Neuraminidase Inhibitor Susceptibility Network (NISN) with the International Society for Influenza and Other Respiratory Virus Diseases (isirv). Read more

To fulfil its objectives of promoting understanding of the development and clinical use of antivirals against respiratory viruses and the emergence of resistance, the Group has organised a series of AVG conferences on specific topics in different geographical locations plus other smaller specialist meetings and workshops.

The Group gratefully acknowledges the contribution of its partners and the generous financial support from many privateand public organisations that have ensured the success of the Group’s programme of events over the past 10 years.




Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo… read more

Protective human antibodies against a conserved epitope in pre- and post- fusion influenza hemagglutinin… read more

Oseltamivir May or May Not Reduce Hospitalizations… read more

Prescription of anti-influenza drugs in Japan, 2014-2020: A retrospective study using open data from the national claims database … read more

Influenza virus cell entry and targeted antiviral development … read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
Visit us on:  facebook  twitter